Post-Thrombotic Syndrome, Iliocaval Obstruction, Venous Compression, and Deep Venous Reconstruction

56.1Definition and presentation

Post-thrombotic syndrome (PTS) is chronic symptomatic venous disease after DVT. Assessment is generally deferred for 3–6 months. Villalta scores of 5–9 indicate mild and 10–14 moderate PTS; a score of at least 15 or a venous ulcer indicates severe PTS. Serial assessment helps distinguish persistent disease from resolving acute symptoms Kahn 2016.

Presenting features of established chronic iliocaval or iliofemoral obstruction include:

• Persistent swelling and heaviness
• Pain and venous claudication
• Skin changes and hyperpigmentation
• Functional limitation or an active venous ulcer (an open wound)

Non-thrombotic iliac vein lesions (including May-Thurner syndrome) present with a similar clinical phenotype of unilateral lower-limb or pelvic venous hypertension, but are caused by extrinsic compression of the iliac vein without prior thrombosis VIVA/AVF/AVLS 2024 · ESVS 2022.

Background review: Mousa and AbuRahma describe May–Thurner anatomy and clinical presentations; contemporary treatment decisions should use current lesion-specific guidance rather than older procedural habits May-Thurner syndrome 2013.

56.2Diagnosis and stratification

Clinical assessment excludes alternative causes of swelling and pain.

Villalta score Kahn 2016

Duplex ultrasound identifies reflux, obstruction signals, and residual thrombotic change. When chronic reconstruction is considered, cross-sectional venous imaging and intravascular ultrasound (IVUS) define the obstructed segment, landing zones, inflow, and outflow. IVUS alters stenting decisions compared with venography alone in iliofemoral venous obstruction SIR 2023 · VIDIO 2017. For non-thrombotic iliac vein lesions, anatomical compression on cross-sectional imaging does not establish the diagnosis unless accompanied by concordant clinical symptoms of deep venous hypertension VIVA/AVF/AVLS 2024.

56.3Medical and conservative management

Acute proximal DVT is managed primarily with anticoagulation to prevent embolism and recurrence. A direct oral anticoagulant is first-line for eligible patients without active cancer, and is preferred over low-molecular-weight heparin bridged to a vitamin K antagonist CHEST 2021 · ESVS 2021. Selected patients with unprovoked proximal DVT receive extended anticoagulation if the bleeding risk is acceptable.

Conservative management of chronic post-thrombotic syndrome centres on compression therapy. Although the SOX trial demonstrated that routine application of elastic compression stockings does not prevent the initial development of PTS after a proximal DVT SOX 2014, compression remains the first-line treatment for established PTS symptoms with compression strength and duration tailored to symptoms and tolerance rather than a mandatory two-year course Kahn 2016.

56.4Treatment decision thresholds

The intervention decision separates acute thrombus removal from chronic post-thrombotic reconstruction. The 2024 EVF-hosted VTE consensus also addresses selected early thrombus removal; it does not replace chronic-obstruction guidance VTE 2024. In acute proximal DVT, routine pharmacomechanical catheter-directed thrombolysis (PCDT) is not indicated. In the ATTRACT trial, PCDT did not reduce overall PTS at 24 months (47% vs 48%) and increased major bleeding (1.7% vs 0.3%) compared with anticoagulation alone ATTRACT 2017. Thrombus removal is reserved for acute iliofemoral DVT with short symptom duration and acceptable bleeding risk CaVenT 2016 · Comerota et al. (2019). Phlegmasia cerulea dolens or impending venous gangrene overrides these selective criteria and mandates urgent thrombus removal (catheter-directed thrombolysis or mechanical or pharmacomechanical thrombectomy), with fasciotomy if compartment syndrome supervenes ESVS 2021.

Chronic post-thrombotic and non-thrombotic iliofemoral obstructions are managed by stenting or open reconstruction only when conservative therapy fails and symptoms align with anatomically suitable disease. Indiscriminate stenting of asymptomatic imaging findings is not indicated VIVA/AVF/AVLS 2024 · SIR 2023.

The management pathway follows an ordered sequence:

1. Treat acute VTE medically with anticoagulation.
2. Evaluate acute iliofemoral DVT for selective early thrombus removal based on symptom duration and bleeding risk.
3. Institute a trial of compression and conservative care for post-thrombotic symptoms.
4. Select patients with severe, refractory symptoms for chronic endovascular stenting or open reconstruction.
5. Pursue no intervention for asymptomatic anatomic compression.

Mechanical thrombectomy evidence

The prospective CLOUT registry enrolled 500 patients at 43 sites and reported improvement in symptoms and venous outcomes after mechanical thrombectomy. It lacked an anticoagulation-only control group. Acute baseline Villalta scores cannot be treated as established PTS, and their subsequent improvement does not prove that thrombectomy prevents PTS or outperforms anticoagulation. These data complement, rather than replace, randomized thrombolysis evidence CLOUT 2023.

C-TRACT randomized 225 patients with moderate or severe PTS and imaging-confirmed iliac obstruction. Stenting plus enhanced antithrombotic treatment and standard care improved six-month VCSS compared with standard care alone (8.1 versus 10.0; adjusted difference −2.0). Quality of life improved, but bleeding was more frequent (11.6% versus 3.6%). This treatment-package comparison does not isolate the effect of stenting alone or establish long-term durability or prevention of PTS after acute DVT Endovascular Therapy 2026.

56.5Endovascular and open reconstruction

Stenting is the preferred intervention for severe, symptomatic chronic iliofemoral and iliocaval obstruction refractory to compression therapy. Inflow, outflow and lesion morphology determine the reconstruction plan. ESVS recommends considering IVUS during iliac outflow intervention (IIa/C); the 2024 NIVL consensus specifically recommends complementary venography and IVUS when assessing a patient for NIVL treatment VIVA/AVF/AVLS 2024 · ESVS 2022.

Acute clot and chronic fibrotic obstruction require different strategies. Selected acute iliofemoral thrombosis may be treated with catheter-directed lysis, mechanical or combined thrombus removal, with a separate decision about residual outflow obstruction. Chronic scar is not an indication for thrombolysis merely because stenting is planned VTE 2024. The ABRE study, a prospective pivotal study of the Abre venous stent, supports the safety and patency of modern dedicated venous stents in symptomatic outflow obstruction ABRE 2022. ABRE enrolled 200 patients across post-thrombotic, non-thrombotic, and acute presentations and reported 12-month primary patency of 88.0%. However, the evidence base remains predominantly observational; a 2025 Cochrane review of stenting versus anticoagulation alone for DVT-related obstruction identified only two randomized trials (134 participants) and found that while secondary occlusion may be reduced at 24 months (RR 0.26), the certainty of evidence for PTS prevention and quality of life is very low Cochrane 2025.

Open or hybrid deep venous reconstruction, including deep venous reflux correction, is reserved for specialized cases where the obstruction or reflux anatomy is not amenable to standard endovascular stenting and symptoms remain severe ESVS 2022 · Deep Venous Reflux Meta-analysis 2023.

56.6Areas of controversy

The magnitude of benefit for early thrombus removal in acute iliofemoral DVT remains contested. While the CaVenT trial demonstrated that additional conventional catheter-directed thrombolysis reduced PTS at 5 years from 71% to 43% (absolute risk reduction 28%, number needed to treat approximately 4) CaVenT 2016, the CAVA trial (using ultrasound-accelerated lysis) did not show a statistically significant reduction at 12 months (29% vs 35%) CAVA 2020. Furthermore, the ATTRACT iliofemoral subgroup demonstrated improvements only in moderate-to-severe PTS (18% vs 28%) rather than overall incidence Comerota et al. (2019).

Earlier guidance and reviews reflect a limited randomized evidence base for venous stenting, with heavy reliance on observational cohorts and device-specific trials SIR 2023 · Cochrane 2025 · Seager 2016. C-TRACT now provides multicenter randomized evidence that iliac-vein stenting plus enhanced antithrombotic therapy and standard care reduces PTS severity and improves quality of life over six months in patients with moderate or severe PTS and iliac-vein obstruction, but increases overall bleeding, mainly non-major bleeding (see Treatment decision thresholds). The treatment-package comparison does not isolate stenting alone, and longer-term benefit and risk remain uncertain Endovascular Therapy 2026.

The exact degree of anatomical compression and symptom severity required to justify stenting in non-thrombotic iliac vein lesions is not uniformly established, leaving the intervention threshold highly reliant on clinical judgment regarding symptom concordance VIVA/AVF/AVLS 2024.

Further reading

• Systematic review and meta-analysis of deep venous reflux correction in chronic venous insufficiency. (2023). Deep venous reflux reconstruction evidence. Deep Venous Reflux Meta-analysis 2023
• Editor's Choice-- A Systematic Review of Endovenous Stenting in Chronic Venous Disease Secondary to Iliac Vein Obstruction. (2016). Iliac obstruction stenting background; historical observational evidence. Seager 2016